GSK plc
Price Action
Technical Summary
STAGE 2 UPTRENDGSK plc is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 85), indicating clear outperformance against the broad market. Earnings growth of 50% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $58.25 | +1.50% | ABOVE |
| 50 SMA | $52.94 | +11.69% | ABOVE |
| 100 SMA | $49.68 | +19.02% | ABOVE |
| 150 SMA | $46.40 | +27.43% | ABOVE |
| 200 SMA | $44.54 | +32.76% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is GSK in an uptrend right now?
GSK has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, GSK is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is GSK overbought or oversold?
GSK's RSI (14) is 58. The stock is in neutral territory, neither overbought nor oversold.
Is GSK outperforming the market?
GSK has a Relative Strength (RS) Rating of 85 out of 99. Yes, GSK is a market leader, outperforming 85% of all stocks over the past 12 months.
Where is GSK in its 52-week range?
GSK is trading at $59.13, which is 96% of its 52-week high ($61.70) and 91% above its 52-week low ($32.38).
How volatile is GSK?
GSK has a Beta of 0.22 and 52-week volatility of 28%. It's less volatile than the S&P 500 - generally more stable.